On this episode of Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, talks with the founder and CEO of ConsejoSano, a patient engagement firm working with diverse, multicultural, multilingual populations about the importance of building relationships and trust when trying to understand opinions and beliefs about COVID-19 vaccination.
Vaccine hesitancy may be one of the contributing factors if the United States does not reach herd immunity to the virus that causes COVID-19. Such hesitancy presents itself in different ways and forms, ranging from outright refusal in conservative rural areas to fears in communities of color to skepticism of science elsewhere.
On this episode of Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, has a conversation with Abner Mason, the founder and CEO of ConsejoSano, a patient engagement firm working with diverse, multicultural, multilingual populations through at-risk providers, health plans, government programs, employers, and other partners.
The two discuss the importance of relationship and trust building and understanding where people are coming from when they have the opinions and beliefs that they hold. They also discuss the role of health plans in COVID-19 vaccinations and how payers and partners can work on upstream issues to address other care gaps.
Listen above or through one of these podcast services:
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More